(Q53083578)

English

Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.

scientific article published on 10 January 2014

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24409939

Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24409939

neovascularization

1 reference

based on heuristic

inferred from title

macular degeneration

1 reference

based on heuristic

inferred from title

Muhammet Kazim Erol

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Ozdemir Ozdemir

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Deniz Turgut Coban

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Basak Bostanci Ceran

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Mehmet Bulut

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

0 references

publication date

10 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24409939

Seminars in Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

108-113

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Choroidal neovascularization

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Tri

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Verteporfin in Photodynamic Therapy (VIP) Study group

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12.

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Intravitreal bevacizumab for subfoveal choroidal neovascularization complicating active central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections.

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2013.839716

21 January 2018

Identifiers

10.3109/08820538.2013.839716

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24409939%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53083578&oldid=1530144408"